[Correspondence] Efficacy of infliximab biosimilars in patients with Crohn's disease
The study by Kristen K J ørgensen and colleagues1 assessed the efficacy of switching maintenance therapy from originator infliximab to the biosimilar CT-P13 in several inflammatory diseases. Because of the potential effects biosimilars could have on health and the cost of health care, this is an active area of debate.2–4
Source: LANCET - Category: General Medicine Authors: Davide Giuseppe Ribaldone, Giorgio Maria Saracco, Marco Astegiano, Rinaldo Pellicano Tags: Correspondence Source Type: research
More News: Crohn's Disease | General Medicine | Health Management | Inflammatory Bowel Disease | Remicade | Study